Two years from today , if everything goes according to plan, Lipitor will go generic. That’s likely to be the end of an era when big drug makers built their businesses around mega-blockbuster drugs that treat common, chronic conditions. In its magazine section this weekend, the Financial Times traced the long arc of the cholesterol drug, which has earned more than $80 billion for Pfizer.

See original here:
Lipitor & the Era of Mega-Blockbusters. (Also: Fungi.)

Share and Enjoy:
  • Print
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google Bookmarks

Tagged with: • • • • • • • • • •

Filed under: Cancer • Cholesterol • Drugs • ED • IT • Lipitor • M&A • Merck • Pfizer • Research • Uncategorized • flu • generic • generics • heal • health • statins

Like this post? Subscribe to my RSS feed and get loads more!